GHK-Cu Results Timeline
What the standard GHK-Cu research protocol looks like phase by phase, over a typical 8–16 weeks cycle. This is the escalation schedule from our full dosing protocol, presented as a timeline rather than a table.
Quick Facts
FREQUENCY5 days/week or 3x/week
CYCLE LENGTH8–16 weeks
DOSE RANGE1.0–2.0 mg per injection
ROUTESubcutaneous injection
Phase-by-Phase Timeline
Loading / Titration
Weeks 1–4
Target dose: 1.0 mg (1000 mcg)
Escalation
Weeks 5–8
Target dose: 1.5 mg (1500 mcg)
Maintenance
Weeks 9–12+
Target dose: 2.0 mg (2000 mcg)
Reported in Research
- ✓0 mg over 4–8 weeks.
- ✓8–12 weeks typical; may extend to 16 weeks.
- ✓Benefits are cumulative and may take 4–6 weeks to appear.
This timeline reflects the structure of the standard GHK-Cu research protocol documented on this site — it is not a guarantee of individual outcomes, and timelines vary between research subjects. All products sold by JA Performance Peptides are intended strictly for laboratory research purposes and are not approved for human consumption, veterinary use, or therapeutic application. Not for human use.